Quick Answer
LeonaBio, Inc. reported R&D Expense of $17.50 million for fiscal year 2025.
LeonaBio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $17.50M | -75.2% |
| 2024 | $70.68M | -24.6% |
| 2023 | $93.79M | +52.6% |
| 2022 | $61.46M | +43.6% |
| 2021 | $42.79M | +222.1% |
| 2020 | $13.29M | +250.3% |
| 2019 | $3.79M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.83M | -84.2% | -22.8% |
| June 30, 2025 | $3.66M | -83.5% | -14.9% |
| March 31, 2025 | $4.30M | -79.7% | -76.0% |
| September 30, 2024 | $17.92M | -34.1% | -19.1% |
| June 30, 2024 | $22.15M | +2.5% | +4.3% |
| March 31, 2024 | $21.24M | -0.3% | -21.9% |
| September 30, 2023 | $27.20M | +60.3% | +25.8% |
| June 30, 2023 | $21.61M | +46.0% | +1.5% |
- LeonaBio, Inc. showed a decrease of -75.2% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, LeonaBio, Inc.’s r&d expense has grown by 361.4% (from $3.79 million to $17.50 million).
- The most recent figure is from LeonaBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: